Abstract:A delayed fetal-to-adult hemoglobin (Hb) switch ameliorates the severity of beta-thalassemia and sickle cell disease. The molecular mechanism underlying the epigenetic dysregulation of the switch is unclear. To explore the potential cis-variants responsible for the Hb switching, we systematically analyzed an 80-kb region spanning the beta-globin cluster using capture-based next-generation sequencing of 1142 Chinese beta-thalassemia persons and identified 31 fetal hemoglobin (HbF)-associated haplotypes of the selected 28 tag regulatory single-nucleotide polymorphisms (rSNPs) in seven linkage disequilibrium (LD) blocks. A Ly1 antibody reactive (LYAR)-binding motif disruptive rSNP rs368698783 (G/A) from LD block 5 in the proximal promoter of hemoglobin subunit gamma 1 (HBG1) was found to be a significant predictor for beta-thalassemia clinical severity by epigenetic-mediated variant-dependent HbF elevation. We found this rSNP accounted for 41.6% of beta-hemoglobinopathy individuals as an ameliorating factor in a total of 2,738 individuals from southern China and Thailand. We uncovered that the minor allele of the rSNP triggers the attenuation of LYAR and two repressive epigenetic regulators DNA methyltransferase 3 alpha (DNMT3A) and protein arginine methyltransferase 5 (PRMT5) from the HBG promoters, mediating allele-biased gamma-globin elevation by facilitating demethylation of HBG core promoter CpG sites in erythroid progenitor cells from beta-thalassemia persons. The present study demonstrates that this common rSNP in the proximal A gamma-promoter is a major genetic modifier capable of ameliorating the severity of thalassemia major through the epigenetic-mediated regulation of the delayed fetal-to-adult Hb switch and provides potential targets for the treatment of beta-hemoglobinopathy.

Genome-wide analysis of aberrantly expressed lncRNAs and miRNAs with associated co-expression and ceRNA networks in β-thalassemia and hereditary persistence of fetal hemoglobin

Changes in Lncrnas and Related Genes in Β-Thalassemia Minor and Β-Thalassemia Major

Identification and characterization of CHD4-associated eRNA as a novel modulator of fetal hemoglobin levels in β-thalassemia

Using microarray analysis to identify genes and pathways that regulate fetal hemoglobin levels

Human m6A-mRNA and lncRNA epitranscriptomic microarray reveal function of RNA methylation in hemoglobin H-constant spring disease

Activation of γ-globin expression by LncRNA-mediated ERF promoter hypermethylation in β-thalassemia

Activation of γ-globin expression by a common variant disrupting IKAROS-binding motif in β-thalassemia

Upregulation of miR‐6747‐3p affects red blood cell lineage development and induces fetal hemoglobin expression by targeting BCL11A in β‐thalassemia

3’HS1 CTCF binding site in human β-globin locus regulates fetal hemoglobin expression

A Genetic Variant Ameliorates Β-Thalassemia Severity by Epigenetic-Mediated Elevation of Human Fetal Hemoglobin Expression

Single-nucleotide-level Mapping of DNA Regulatory Elements That Control Fetal Hemoglobin Expression

3′HS1 CTCF binding site in human β-globin locus regulates fetal hemoglobin expression

Fetal Hemoglobin Regulation in Beta-Thalassemia

Genome-wide methylation and gene-expression analyses in thalassemia

Fibrillarin modulates fetal hemoglobin silencing

Long noncoding RNA <i>HBBP1</i> enhances -globin expression through the ETS transcription factor ELK1

Genetic modifications of EGLN1 reactivate HbF production in β0-thalassemia/HbE

Plasma proteome profiling combined with clinical and genetic features reveals the pathophysiological characteristics of β-thalassemia

AB034. Hemoglobinopathies in China and SEA: Rapid Targeted Deep Sequencing for Molecular Screening and Clinical Genotyping in Subjects with Hemoglobinopathies

A natural DNMT1 mutation elevates the fetal hemoglobin level via epigenetic derepression of the γ-globin gene in β-thalassemia

Long Non-Coding RNA H19 Leads to Upregulation of γ-Globin Gene Expression during Erythroid Differentiation